Home
Storia in 2 fonti
Updated: Odyssey CEO talks about $279M IPO and building a 'permanent' biotech
Odyssey Therapeutics raised $279 million in an upsized IPO priced at $18 a share, with the autoimmune disease biotech set to begin Nasdaq trading Friday.
- ·
biopharmadive.com
Odyssey, on second try, snags $279M in an IPO
After withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new biotech stock offerings — while boosting its haul even…
- ·
endpoints.news
Updated: Odyssey CEO talks about $279M IPO and building a 'permanent' biotech
Odyssey Therapeutics raised $279 million in an upsized IPO priced at $18 a share, with the autoimmune disease biotech set to begin Nasdaq trading Friday.